Invention Grant
- Patent Title: Amidated peptides and their deamidated counterparts displayed by non-HLA-A*02 for use in immunotherapy against different types of cancers preliminary class
-
Application No.: US18305928Application Date: 2023-04-24
-
Publication No.: US11952409B2Publication Date: 2024-04-09
- Inventor: Jens Hukelmann , Heiko Schuster , Lena Wullkopf , Christoph Schraeder , Jens Fritsche , Daniel Johannes Kowalewski , Michael Roemer , Oliver Schoor
- Applicant: Immatics Biotechnologies GmbH
- Applicant Address: DE Tuebingen
- Assignee: IMMATICS BIOTECHNOLOGIES GMBH
- Current Assignee: IMMATICS BIOTECHNOLOGIES GMBH
- Current Assignee Address: DE Tuebingen
- Agency: McBee Moore & Vanik IP, LLC
- The original application number of the division: US17489446 2021.09.29
- Main IPC: C07K14/725
- IPC: C07K14/725 ; A61K35/17 ; A61K38/00 ; C07K14/74 ; C07K16/28
Abstract:
The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 113, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
Public/Granted literature
Information query
